Analysis of retrospective data suggests a signal that metformin may be associated with decreased risk of any AMD. It should be interpreted with caution because of the failure to meet statistical significance, the small number of studies, and the limitation of routine record data. However prospective studies are warranted in generalizable populations without diabetes, of varied ethnicities, and AMD stages. Clinical trials are needed to determine if metformin has efficacy in treating early and late-stage AMD.
No takes yet. Share an insight, caveat, or question.
Romdhoniyyah et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: